Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jean-Charles Fruchart

Showing results (41-50 of 167) with videos related to

Pageof 17
Sort By:
Clinical Chemistry and Laboratory Medicine|July 20, 2007
Apolipoprotein A-V gene polymorphisms in subjects with metabolic syndromeLoredan Stefan Niculescu, Jamila Fruchart-Najib, Jean-Charles Fruchart, et al.
The Journal of Biological Chemistry|July 16, 2002
Peroxisome proliferator-activated receptor alpha (PPARalpha ) turnover by the ubiquitin-proteasome system controls the ligand-induced expression level of its target genesChristophe Blanquart, Olivier Barbier, Jean-Charles Fruchart, et al.
Biochemical and Biophysical Research Communications|June 5, 2004
Different ways to regulate the PPARalpha stabilityChristophe Blanquart, Roxane Mansouri, Jean-Charles Fruchart, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|January 21, 2006
Modulation of hepatic inflammatory risk markers of cardiovascular diseases by PPAR-alpha activators: clinical and experimental evidenceAlberto Zambon, Philippe Gervois, Paolo Pauletto, et al.
Current Medical Research and Opinion|August 25, 2004
Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid--a position paper developed by the European Consensus Panel on HDL-CM John Chapman, Gerd Assmann, Jean-Charles Fruchart, et al.
Biochimica Et Biophysica Acta|April 13, 2007
Safety issues and prospects for future generations of PPAR modulatorsAnne Rubenstrunk, Rémy Hanf, Dean W Hum, et al.
Molecular Endocrinology (Baltimore, Md.)|May 8, 2004
The protein kinase C signaling pathway regulates a molecular switch between transactivation and transrepression activity of the peroxisome proliferator-activated receptor alphaChristophe Blanquart, Roxane Mansouri, Réjane Paumelle, et al.
Journal of Cardiovascular Pharmacology|April 13, 2004
Fenofibrate increases homocystinemia through a PPARalpha-mediated mechanismGérald Luc, Nelly Jacob, Muriel Bouly, et al.
Annals of Medicine|February 2, 2006
Is apolipoprotein A5 a novel regulator of triglyceride-rich lipoproteins?Heidelinde Jakel, Maxime Nowak, Audrey Helleboid-Chapman, et al.
Biochimica Et Biophysica Acta|February 8, 2003
SR-BI does not require raft/caveola localisation for cholesteryl ester selective uptake in the human adrenal cell line NCI-H295ROlivier Briand, Sophie Lestavel, Antoine Pilon, et al.
Pageof 17

Showing results (41-50 of 167) with videos related to

Sort By:
Pageof 17
Clinical Chemistry and Laboratory Medicine|July 20, 2007
Apolipoprotein A-V gene polymorphisms in subjects with metabolic syndromeLoredan Stefan Niculescu, Jamila Fruchart-Najib, Jean-Charles Fruchart, et al.
The Journal of Biological Chemistry|July 16, 2002
Peroxisome proliferator-activated receptor alpha (PPARalpha ) turnover by the ubiquitin-proteasome system controls the ligand-induced expression level of its target genesChristophe Blanquart, Olivier Barbier, Jean-Charles Fruchart, et al.
Biochemical and Biophysical Research Communications|June 5, 2004
Different ways to regulate the PPARalpha stabilityChristophe Blanquart, Roxane Mansouri, Jean-Charles Fruchart, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|January 21, 2006
Modulation of hepatic inflammatory risk markers of cardiovascular diseases by PPAR-alpha activators: clinical and experimental evidenceAlberto Zambon, Philippe Gervois, Paolo Pauletto, et al.
Current Medical Research and Opinion|August 25, 2004
Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid--a position paper developed by the European Consensus Panel on HDL-CM John Chapman, Gerd Assmann, Jean-Charles Fruchart, et al.
Biochimica Et Biophysica Acta|April 13, 2007
Safety issues and prospects for future generations of PPAR modulatorsAnne Rubenstrunk, Rémy Hanf, Dean W Hum, et al.
Molecular Endocrinology (Baltimore, Md.)|May 8, 2004
The protein kinase C signaling pathway regulates a molecular switch between transactivation and transrepression activity of the peroxisome proliferator-activated receptor alphaChristophe Blanquart, Roxane Mansouri, Réjane Paumelle, et al.
Journal of Cardiovascular Pharmacology|April 13, 2004
Fenofibrate increases homocystinemia through a PPARalpha-mediated mechanismGérald Luc, Nelly Jacob, Muriel Bouly, et al.
Annals of Medicine|February 2, 2006
Is apolipoprotein A5 a novel regulator of triglyceride-rich lipoproteins?Heidelinde Jakel, Maxime Nowak, Audrey Helleboid-Chapman, et al.
Biochimica Et Biophysica Acta|February 8, 2003
SR-BI does not require raft/caveola localisation for cholesteryl ester selective uptake in the human adrenal cell line NCI-H295ROlivier Briand, Sophie Lestavel, Antoine Pilon, et al.
Pageof 17